Mabpharm Limited, a Taizhou, Jiangsu Province-based biotechnology company, has filed for an initial public offering in Hong Kong, becoming the latest Chinese biotech firm rushing for a Hong Kong IPO.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?